Prucalopride might improve intestinal motility by promoting the regeneration of the enteric nervous system in diabetic rats

Wang,Yun; Xu,Xinyu; Lin,Lin

doi:10.3892/ijmm.2022.5143

Prucalopride might improve intestinal motility by promoting the regeneration of the enteric nervous system in diabetic rats

Authors:
- Yun Wang
- Xinyu Xu
- Lin Lin
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Spleen and Stomach Disease, Nanjing Integrated Traditional Chinese and Western Medicine Hospital, Nanjing, Jiangsu 210014, P.R. China
Published online on: May 10, 2022 https://doi.org/10.3892/ijmm.2022.5143
Article Number: 87
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate whether prucalopride, as a 5‑hydroxytryptamine 4 (5‑HT4) receptor agonist, improved intestinal motility by promoting the regeneration of the enteric nervous system (ENS) in rats with diabetes mellitus (DM). A rat model of DM was established using an intraperitoneal injection of streptozotocin. The rats were randomly divided into four groups of 6 rats/group: Control, DM (DM model), DM + A (5 µg/kg prucalopride) and DM + B (10 µg/kg prucalopride). The rats in the Control group were given an equal volume of citric acid solvent. After successful model establishment, high blood glucose levels were maintained for 2 weeks before administration of prucalopride. The colonic transit time was measured using the glass bead discharge method. It was revealed that the colonic transit time of diabetic rats was the longest, and this was significantly shortened in the DM + B group. Subsequently, the colons were collected. The expression levels of Nestin, glial fibrillary acidic protein (GFAP), SOX10, RNA‑binding protein human antigen D (HuD) and ubiquitin thiolesterase (PGP9.5) were determined via immunohistochemical analysis. Immunofluorescence double staining of 5‑HT4 + Nestin and Ki67 + Nestin was performed. The 5‑HT level was measured using ELISA. Compared with that in the control group, Nestin expression was significantly increased in the DM and DM + A groups, and it was concentrated in columnar epithelial cells and the mesenchyme. Furthermore, the expression levels of Nestin in the DM + A group were higher than those in the DM group. No difference was observed in the expression levels of Nestin between the DM + B group and the Control group. The expression levels of 5‑HT protein were highest in the Control group; however, the expression levels of 5‑HT protein in the DM group, DM + A group and DM + B group exhibited an increasing trend. Similar trends in the expression of 5‑HT4 and Nestin were not observed; however, similar trends in the expression of Nestin and Ki67 were observed. The expression levels of GFAP, SOX10, PGP9.5 and Ki67 in the DM + A and DM + B groups were higher compared with those in the DM group. In the DM + A group, HuD expression was decreased compared with that in the Control group but it was markedly higher compared with that in the DM group. In conclusion, prucalopride may improve intestinal motility by promoting ENS regeneration in rats with DM.

View Figures

View References

1	NCD Risk Factor Collaboration (NCD -RisC): Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 387:1513–1530. 2016. View Article : Google Scholar
2	Yoo H, Choo E and Lee S: Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index. BMC Endocr Disord. 20:1222020. View Article : Google Scholar :
3	Horowitz M and Samsom M: Gastrointestinal function in diabetes mellitus. Chichester: John Wiley & Sons, Ltd; pp. 1–337. 2004
4	Kalra S, Zargar AH, Jain SM, Sethi B, Chowdhury S, Singh AK, Thomas N, Unnikrishnan AG, Thakkar PB and Malve H: Diabetes insipidus: The other diabetes. Indian J Endocrinol Metab. 20:9–21. 2016. View Article : Google Scholar : PubMed/NCBI
5	Krishnan B, Babu S, Walker J, Walker AB and Pappachan JM: Gastrointestinal complications of diabetes mellitus. World J Diabetes. 4:51–63. 2013. View Article : Google Scholar : PubMed/NCBI
6	Azpiroz F and Malagelada C: Diabetic neuropathy in the gut: Pathogenesis and diagnosis. Diabetologia. 59:404–408. 2016. View Article : Google Scholar
7	Ordög T, Hayashi Y and Gibbons SJ: Cellular pathogenesis of diabetic gastroenteropathy. Minerva Gastroenterol Dietol. 55:315–343. 2009.PubMed/NCBI
8	Yarandi SS and Srinivasan S: Diabetic gastrointestinal motility disorders and the role of enteric nervous system: Current status and future directions. Neurogastroenterol Motil. 26:611–624. 2014. View Article : Google Scholar : PubMed/NCBI
9	Domènech A, Pasquinelli G, De Giorgio R, Gori A, Bosch F, Pumarola M and Jiménez M: Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNβ transgenic mice. Int J Exp Pathol. 92:400–412. 2011. View Article : Google Scholar
10	Du F, Wang L, Qian W and Liu S: Loss of enteric neurons accompanied by decreased expression of GDNF and PI3K/Akt pathway in diabetic rats. Neurogastroenterol Motil. 21:1229–e114. 2009. View Article : Google Scholar : PubMed/NCBI
11	Furlan MM, Molinari SL and Miranda Neto MH: Morphoquantitative effects of acute diabetes on the myenteric neurons of the proximal colon of adult rats. Arq Neuropsiquiatr. 60:576–581. 2002. View Article : Google Scholar : PubMed/NCBI
12	Ordög T: Interstitial cells of Cajal in diabetic gastroenteropathy. Neurogastroenterol Motil. 20:8–18. 2008. View Article : Google Scholar : PubMed/NCBI
13	Lin HZ, Sarosiek I, Forster J, Damjanov I, Hou Q and McCallum RW: Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis. Neurogastroenterol Motility. 22:56–61. 2010.
14	Rao M and Gershon MD: The bowel and beyond: The enteric nervous system in neurological disorders. Nat Rev Gastroenterol Hepatol. 13:517–528. 2016. View Article : Google Scholar : PubMed/NCBI
15	Lake JI and Heuckeroth RO: Enteric nervous system development: Migration, differentiation, and disease. Am J Physiol Gastrointest Liver Physiol. 305:G1–G24. 2013. View Article : Google Scholar : PubMed/NCBI
16	Farrugia G: Histologic changes in diabetic gastroparesis. Gastroenterol Clin North Am. 44:31–38. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ihana-Sugiyama N, Nagata N, Yamamoto-Honda R, Izawa E, Kajio H, Shimbo T, Kakei M, Uemura N, Akiyama J and Noda M: Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors. World J Gastroenterol. 22:3252–3260. 2016. View Article : Google Scholar : PubMed/NCBI
18	Becker L, Kulkarni S, Tiwari G, Micci MA and Pasricha PJ: Divergent fate and origin of neurosphere-like bodies from different layers of the gut. Am J Physiol Gastrointest Liver Physiol. 302:G958–G965. 2012. View Article : Google Scholar : PubMed/NCBI
19	Burns AJ and Pachnis V: Development of the enteric nervous system: Bringing together cells, signals and genes. Neurogastroenterol Motil. 21:100–102. 2009. View Article : Google Scholar : PubMed/NCBI
20	Laranjeira C, Sandgren K, Kessaris N, Richardson W, Potocnik A, Vanden Berghe P and Pachnis V: Glial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury. J Clin Invest. 121:3412–3424. 2011. View Article : Google Scholar : PubMed/NCBI
21	Joseph NM, He S, Quintana E, Kim YG, Núñez G and Morrison SJ: Enteric glia are multipotent in culture but primarily form glia in the adult rodent gut. J Clin Invest. 121:3398–3411. 2011. View Article : Google Scholar : PubMed/NCBI
22	Matsuyoshi H, Kuniyasu H, Okumura M, Misawa H, Katsui R, Zhang GX, Obata K and Takaki M: A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult. Neurogastroenterol Motil. 22:806–813.e226. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bixby S, Kruger GM, Mosher JT, Joseph NM and Morrison SJ: Cell-intrinsic differences between stem cells from different regions of the peripheral nervous system regulate the generation of neural diversity. Neuron. 35:643–656. 2002. View Article : Google Scholar : PubMed/NCBI
24	Kruger GM, Mosher JT, Bixby S, Joseph N, Iwashita T and Morrison SJ: Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness. Neuron. 35:657–669. 2002. View Article : Google Scholar : PubMed/NCBI
25	Heanue TA and Pachnis V: Enteric nervous system development and Hirschsprung's disease: Advances in genetic and stem cell studies. Nat Rev Neurosci. 8:466–479. 2007. View Article : Google Scholar : PubMed/NCBI
26	Burns AJ, Goldstein AM, Newgreen DF, Stamp L, Schäfer KH, Metzger M, Hotta R, Young HM, Andrews PW, Thapar N, et al: White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies. Dev Biol. 417:229–251. 2016. View Article : Google Scholar : PubMed/NCBI
27	Ibrahim A, Ali RAR, Manaf MRA, Ahmad N, Tajurruddin FW, Qin WZ, Desa SHM and Ibrahim NM: Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial. PLoS One. 15:e02446802020. View Article : Google Scholar
28	Shafe AC, Lee S, Dalrymple JS and Whorwell PJ: The LUCK study: Laxative usage in patients with GP-diagnosed constipation in the UK, within the general population and in pregnancy. An epidemiological study using the general practice research database (GPRD). Therap Adv Gastroenterol. 4:343–363. 2011. View Article : Google Scholar : PubMed/NCBI
29	Menees SB, Guentner A, Chey SW, Saad R and Chey WD: How Do US gastroenterologists use over-the-counter and prescription medications in patients with gastroesophageal reflux and chronic constipation? Am J Gastroenterol. 110:1516–1525. 2015. View Article : Google Scholar : PubMed/NCBI
30	Gonzalez-Martinez MA, Ortiz-Olvera NX and Mendez-Navarro J: Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol. 48:21–28. 2014. View Article : Google Scholar
31	Hennessy S, Leonard CE, Newcomb C, Kimmel SE and Bilker WB: Cisapride and ventricular arrhythmia. Br J Clin Pharmacol. 66:375–385. 2008. View Article : Google Scholar : PubMed/NCBI
32	Wysowski DK, Corken A, Gallo-Torres H, Talarico L and Rodriguez EM: Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol. 96:1698–1703. 2001. View Article : Google Scholar : PubMed/NCBI
33	Thompson CA: Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm. 64:10202007. View Article : Google Scholar : PubMed/NCBI
34	Pan H and Gershon MD: Activation of intrinsic afferent pathways in submucosal ganglia of the guinea pig small intestine. J Neurosci. 20:3295–3309. 2000. View Article : Google Scholar : PubMed/NCBI
35	Belkind-Gerson J, Carreon-Rodriguez A, Benedict LA, Steiger C, Pieretti A, Nagy N, Dietrich J and Goldstein AM: Nestin-expressing cells in the gut give rise to enteric neurons and glial cells. Neurogastroenterol Motil. 25:61–69.e7. 2013. View Article : Google Scholar
36	Liu MT, Kuan YH, Wang J, Hen R and Gershon MD: 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci. 29:9683–9699. 2009. View Article : Google Scholar : PubMed/NCBI
37	Bouras EP, Michael C, Burton DD, Thomforde G, McKinzie S and Zinsmeister AR: Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 120:354–360. 2001. View Article : Google Scholar : PubMed/NCBI
38	Karin S and Ken W: Chapter 35-gastrointestinal drugs. Side Eff Drugs Annu. 37:433–459. 2015. View Article : Google Scholar
39	Bharucha AE, Wouters MM and Tack J: Existing and emerging therapies for managing constipation and diarrhea. Curr Opin Pharmacol. 37:158–166. 2017. View Article : Google Scholar : PubMed/NCBI
40	Ueno N, Inui A and Satoh Y: The effect of mosapride citrate on constipation in patients with diabetes. Diabetes Res Clin Pract. 87:27–32. 2010. View Article : Google Scholar
41	Gershon MD and Liu MT: Serotonin and neuroprotection in functional bowel disorders. Neurogastroenterol Motil. 19(Suppl 2): S19–S24. 2007. View Article : Google Scholar
42	Bassotti G, Gambaccini D and Bellini M: Prucalopride succinate for the treatment of constipation: An update. Expert Rev Gastroenterol Hepatol. 10:291–300. 2016. View Article : Google Scholar
43	Omer A and Quigley EMM: An update on prucalopride in the treatment of chronic constipation. Therap Adv Gastroenterol. 10:877–887. 2017. View Article : Google Scholar : PubMed/NCBI
44	Bassotti G, Usai Satta P and Bellini M: Prucalopride for the treatment of constipation: A view from 2015 and beyond. Expert Rev Gastroenterol Hepatol. 13:257–262. 2019. View Article : Google Scholar : PubMed/NCBI
45	Garnock-Jones KP: Prucalopride: A review in chronic idiopathic constipation. Drugs. 76:99–110. 2016. View Article : Google Scholar
46	Daniali M, Nikfar S and Abdollahi M: An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation. Expert Opin Pharmacother. 20:2073–2080. 2019. View Article : Google Scholar : PubMed/NCBI
47	Xie F, Lei J, Ran M, Li Y, Deng L, Feng J, Zhong Y and Li J: Attenuation of diabetic nephropathy in diabetic mice by fasudil through regulation of macrophage polarization. J Diabetes Res. 2020:41269132020. View Article : Google Scholar : PubMed/NCBI
48	McClain J, Grubišić V, Fried D, Gomez-Suarez RA, Leinninger GM, Sévigny J, Parpura V and Gulbransen BD: Ca²⁺ responses in enteric glia are mediated by connexin-43 hemichannels and modulate colonic transit in mice. Gastroenterology. 146:497–507.e1. 2014. View Article : Google Scholar
49	Butler Tjaden NE and Trainor PA: The developmental etiology and pathogenesis of Hirschsprung disease. Transl Res. 162:1–15. 2013. View Article : Google Scholar : PubMed/NCBI
50	Nagy N and Goldstein AM: Enteric nervous system development: A crest cell's journey from neural tube to colon. Semin Cell Dev Biol. 66:94–106. 2017. View Article : Google Scholar : PubMed/NCBI
51	Kiefer JC: Back to basics: Sox genes. Dev Dyn. 236:2356–2366. 2007. View Article : Google Scholar : PubMed/NCBI
52	Sarkar A and Hochedlinger K: The sox family of transcription factors: Versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 12:15–30. 2013. View Article : Google Scholar : PubMed/NCBI
53	Hurst-Kennedy J, Chin LS and Li L: Ubiquitin C-terminal hydrolase l1 in tumorigenesis. Biochem Res Int. 2012:1237062012. View Article : Google Scholar : PubMed/NCBI
54	Burger AM and Seth AK: The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur J Cancer. 40:2217–2229. 2004. View Article : Google Scholar : PubMed/NCBI
55	Uesaka T, Nagashimada M and Enomoto H: Neuronal differentiation in schwann cell lineage underlies postnatal neurogenesis in the enteric nervous system. J Neurosci. 35:9879–9888. 2015. View Article : Google Scholar : PubMed/NCBI
56	Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol. 1:199–206. 1990.PubMed/NCBI
57	Lendahl U, Zimmerman LB and Mckay RD: CNS stem cells express a new class of intermediate filament protein. Cell. 60:585–595. 1990. View Article : Google Scholar : PubMed/NCBI
58	Dahlstrand J, Lardelli M and Lendahl U: Nestin mRNA expression correlates with the central nervous system progenitor cell state in many, but not all, regions of developing central nervous system. Brain Res Dev Brain Res. 84:109–129. 1995. View Article : Google Scholar : PubMed/NCBI
59	Zheng Z, Chen B, Jin Z, Gao M, Tang C, Mao Y, Qu Y and Liu Y: Downregulation of P2Y2 and HuD during the development of the enteric nervous system in fetal rats with anorectal malformations. Mol Med Rep. 20:1297–1305. 2019.PubMed/NCBI
60	Giorgio RD, Volta U, Stanghellini V, Cogliandro RF, Barbara G, Corinaldesi R, Towns R, Guo C, Hong S and Wiley JW: Neurogenic chronic intestinal pseudo-obstruction: Antineuronal antibody-mediated activation of autophagy via Fas. Gastroenterology. 135:601–609. 2008. View Article : Google Scholar : PubMed/NCBI
61	Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, Kanai Y and Hirohashi S: Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. Am J Clin Pathol. 134:71–79. 2010. View Article : Google Scholar : PubMed/NCBI
62	Kostouros A, Koliarakis I, Natsis K, Spandidos D, Tsatsakis A and Tsiaoussis J: Large intestine embryogenesis: Molecular pathways and related disorders (Review). Int J Mol Med. 46:27–57. 2020.PubMed/NCBI
63	Gomes FC, Paulin D and Moura Neto V: Glial fibrillary acidic protein (GFAP): Modulation by growth factors and its implication in astrocyte differentiation. Braz J Med Biol Res. 32:619–631. 1999. View Article : Google Scholar : PubMed/NCBI
64	Tong X, Li L, Li X, Heng L, Zhong L, Su X, Rong R, Hu S, Liu W, Jia B, et al: SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway. Oncotarget. 5:10571–10583. 2014. View Article : Google Scholar : PubMed/NCBI
65	Miller I, Min M, Yang C, Tian C, Gookin S, Carter D and Spencer SL: Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 24:1105–1112.e5. 2018. View Article : Google Scholar : PubMed/NCBI